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Background: People with type 1 diabetes who use electronic self-help tools register a large amount of information
about their disease on their participating devices; however, this information is rarely utilized beyond the immediate
investigation. We have developed a diabetes diary for mobile phones and a statistics-based feedback module,
which we have named Diastat, to give data-driven feedback to the patient based on their own data.
Method: In this study, up to 40 participants will be given a smartphone on which is loaded a diabetes self-help
application (app), the Few Touch Application (FTA). Participants will be randomized into two groups to be given
access to Diastat 4 or 12 weeks, respectively after receiving the smartphone, and will use the FTA with Diastat for 8
weeks after this point. The primary endpoint is the frequency of high and low blood-glucose measurements.
Discussion: The study will investigate the effect of data-driven feedback to patients. Our hypothesis is that this will
improve glycemic control and reduce variability. The endpoints are robust indicators that can be assembled with
minimal effort by the patient beyond normal routine.
Trial registration: Clinicaltrials.gov: NCT01774149
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recognitionBackground
Patients with type 1 diabetes (T1D) on self-measured
blood glucose (SMBG) regimens need to manage a com-
plex and challenging condition, particularly when deciding
their insulin administration. The interactions between
many variables means that the decision-making process is
difficult and leads to poorly regulated blood glucose for
many patients [1]. Patients who use electronic aids such as
blood-glucose monitors and mobile phone applications
(apps) gather large amounts of data on their own disease
on these units. The goal of our study is to investigate
whether statistical analysis and visualization of data on
mobile phones leads to better control of blood glucose for
adults with T1D. We have developed a mobile phone-
based application (app) for the Android platform called
the Few Touch Application (FTA), and an additional mod-
ule for data analysis, called Diastat. .The hypothesis is that* Correspondence: stein.olav.skrovseth@telemed.no
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reproduction in any medium, provided the orgiving this type of data-driven feedback to patients will im-
prove glycemic control.
Diastat was developed based on knowledge from a pre-
vious data-gathering study performed in 2011, in which 30
patients used an earlier version of the FTA for 3 months.
Of these 30 patients, 18 used the application actively, and
thus allowed us to gather data on which to build the algo-
rithms to be tested in this study [2].
Diastat relies in part on precise carbohydrate counting
and recording. This is not commonly applied rigorously by
diabetes patients in Norway, and thus there is a need to
educate patients about monitoring their carbohydrate in-
take. There is evidence that carbohydrate counting itself
improves glycemic control [3,4], and this study does not
aim to test this. Thus, to remove this as a potential con-
founder, all enrolled patients will receive training in carbo-
hydrate counting at the beginning of the study, and the
study will use a stepped-wedge design with two groups, to
ensure that the motivation for counting is equal in
both groups.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hemoglobin (HbA1c) is commonly used as an indicator of
how well regulated a patient’s blood-glucose levels is. Re-
cently, attention has been focused on glucose variability as
a complementary indicator of glucose control [5]. Variabil-
ity is difficult to define precisely in SMBG, but the rate of
low and high measurements beyond given thresholds is a
reasonably good, simple, and robust indicator of glycemic
control, as it is directly related to other measures of
glycemic variability such as low or high blood glucose
index [6].Design
The study is a two-group, stepped-wedge randomized con-
trolled trial [7], with no blinding of participants. Partici-
pants will be randomized into two equal size groups, G1
and G2. Both groups will run the FTA without Diastat for 4
weeks, after which Diastat will be turned on for G1. After 8
more weeks, G2 will also receive access to Diastat. Both
groups will run the FTA with Diastat for 8 weeks, so that
G1 will finish the study in week 12 and G2 will finish in
week 20. Data registered on the phone consists of blood-
glucose measurements, insulin administrations, carbohy-
drate intake, physical activity, and comments, and all data
registered on the phone will be automatically transferred to
a secure server. The study design and patient flow is sum-
marized in Figure 1. The primary comparison points are at
the start of study and after 12 weeks when G1 will have
used Diastat for 8 weeks, and the other group is just
starting its use. Thus, adjusting for repeated time points is
not a concern in the sample-size calculation [8].Figure 1 Patient flow in the study. HbA1c measurements
indicated by dashed lines, endpoint monitoring periods are shaded.The study was submitted for approval by the regional
ethics committee (REC North, case no. 2011/1939), who
waived the study as not required for submission. The
Norwegian data inspectorate approved the data handling
protocol on 28 January 2013.
Randomization
After the first meeting, the study population will be ran-
domized by assigning a number to each participant, and
then randomizing using the sample command in the
R software [9]. Randomization will not be stratified.
Study population
Participants will be recruited from all eligible patients reg-
istered at the Division of Internal Medicine, University
Hospital of North Norway (UNN). Inclusion criteria are
that patients must: be older than 18 years; have had a
diagnosis of T1D for at least 1 year; and have basic
familiarity with mobile phones, and use a mobile phone
on a daily basis.
Exclusion criteria are: pregnancy; inability to under-
stand or conform to the guidelines when presented with
the app; and severe complications attributed to the dia-
betes that would render participation unethical or med-
ically challenging, as determined by the participating
physician. Use of insulin pumps or continuous glucose
meters is not an exclusion criterion in itself, but the
patient must commit to use FTA and traditional SMBG
as part of their treatment in the study period.
Intervention
All participants will be offered a mobile phone with FTA
installed. A participant can choose to use their own phone
on condition that it is compatible, that is, that it runs An-
droid version 2.3 or later, has a screen resolution at least
480 × 800 pixels and is Bluetooth-enabled. Phones not
previously tested with the application must be certified as
suitable. Participants choosing to use their own phone will
receive compensation if they complete the study. All par-
ticipants who complete the study can keep the phones and
app, and continue usage after the study ends, but technical
support will be limited after this point.
Participants will also be given a blood glucose meter
(OneTouch® UltraMini®; LifeScan Inc., Milpitas, CA, USA)
and a connected Bluetooth adapter (Polytel® Glucose
Meter Accessory; Polymap Wireless, Tuscon, AZ, USA)
that is configured for their phone. Configuration will hap-
pen either before the initial meeting for the provided
handsets or will occur on site at the initial meeting if the
participant chooses to use their own phone.
All patients will be instructed to measure their blood
glucose with the provided blood glucose monitoring
system at least five times per day, and when suspecting
hypoglycemia or hyperglycemia. Because data are
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searchers will be able to monitor the data for safety is-
sues. Although this is considered unlikely, we can thus
ensure that the intervention does not significantly in-
crease the chance of severe hypoglycemic events.
Initial meeting
At the initial meeting, all patients will be informed in de-
tail about the study, will receive training in carbohydrate
counting by a nutrition specialist, and will be shown by
the project team how to use the app. Participants will then
be given a phone with FTA pre-installed, or for those par-
ticipants who prefer to use their own phones, FTA will be
installed for them. Participation at this initial seminar is
required for study inclusion, and patients will be required
to sign a consent form of consent and forms outlining
the conditions under which they receive the provided
equipment.
Follow-up meeting
All participants will attend a follow-up meeting before
Diastat is activated on their phone. During this meeting,
participants will be able to give feedback on the applica-
tion, and they will be retrained in use of the Diastat mod-
ule. HbA1c will also be measured at this meeting for the
G2 group.
Diastat
The Diastat module consists of three separate parts,
which are briefly described below.
Periodicity
Periodicity is the ‘typical’ blood glucose over 24 hours
and over 1 week, and is shown graphically along with
uncertainty estimates. The calculated 24-hour value and
variation is shown on the app's main page.Trend
Multi-scale analysis of registered blood glucose is
performed using the cSiZer-method [10], and if there is
a significant trend on any scale, this is shown in the
graphic trend view. Any current, short-scale (less than
48 hours) trend is shown on the main page.
Situation matching
When participants record their insulin injection, they
can see a list of similar situations to the current situ-
ation, along with subsequent blood-glucose readings in
those situations [11]. Those situations are matched and
ranked based on available data in the application and a
dynamic metric on those data. Thus patients have a
case-based reasoning tool to aid in the decision making
when administering insulin.Recruitment
All patients will be recruited at the Division of Internal
Medicine at UNN, where all eligible patients are shown
a presentation of the project on a tablet and given an in-
formation letter during scheduled visits. If they agree to
participation, their participating information will be de-
livered to the principal investigator at planned intervals,
and they will be invited to the 2-day initial seminar.
Outcome measures
Primary outcome is number of low and high blood-
glucose measurements per week. The limits for high and
low blood glucose have been determined based on the re-
sults from the previous study, so that there should be on
average a similar frequency of high and low readings.
Based on the data from the previous study [2] and the fre-
quency of the respective events, we have defined the nor-
mal range as 4–15 mmol/l, which provides for an equal
number of events (roughly 5–6 events per week) on each
side of this range. Patients will be encouraged to measure
their blood glucose whenever they suspect high or low
values, and to measure at least five times per day.
Blood-glucose data will be transferred automatically via
a Bluetooth adapter from the glucose meter to the phone,
and from there to a secure server to which the researchers
have access. Thus, there will be no need for any special ac-
tion by the participants to obtain the outcome.
Secondary outcomes are: 1) HbA1c measured at the
initial seminar, the follow-up meeting, and the end of
study; and 2) participant satisfaction with the applica-
tion, measured by a questionnaire at the end of study,
using the System Usability Scale [12]. Patient empower-
ment will also be measured using the Diabetes Em-
powerment Scale-Short Form [13] at the start and end
of the study.
Sample-size calculation
Sample size is calculated based on number of hypoglycemic
events, with a significance level of 5% and power of 80%.
We assume that for any patient, the rate of events during a
time period follows a Poisson distribution, which is sup-
ported by the previous study data. A 20% reduction in the
rate of hypoglycemic events per time unit requires a time-
sample size of Nt = 353/r, where r is the baseline rate [14].
Assuming a baseline rate of r = 6 events/week, we arrive at
59 participant-weeks in each group, or for a 4-week surveil-
lance period, 15 participants per group. To account for
withdrawal and some participants having low utilization of
the equipment, we are aiming for a total of 40 participants.
Analysis
The endpoints will be analyzed per protocol with stand-
ard statistical tests using the standard R software pack-
age [9]. Additionally, intention-to-treat analysis will be
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protocol (for example, not registering blood glucose to a
sufficient degree) will be excluded from the analysis.
Specifically, anyone with fewer than 4 glucose measure-
ments for less than 50% of their participating days will
be excluded.Discussion
The study will, using delayed start, be able to detect
changes in the primary endpoint and HbA1c both be-
tween the groups in the first 3 months, and by using the
patients in G2 as their own control. Controlling blood
glucose to a sufficient degree is a major challenge for pa-
tients with T1D, and the study will investigate if giving
advanced data-driven feedback of this type can provide
better control. Variability in blood glucose is considered
an important factor for glucose management, comple-
mentary to HbA1c. Thus, the primary endpoint in this
study aims to measure precisely the variability rather
than the long-term blood glucose. Using HbA1c and
questionnaires allows us to obtain more complete infor-
mation on the effect on the patients.
Assessing variability using SMBG measurements is dif-
ficult, and the measures we have chosen could be im-
proved upon. However, the measures are robust
indicators, which, together with the automatic transfer
of values, should ensure that we get a complete picture
with minimal intervention by the participants. The
choice of number of events as outcome mean thats a
realistic sample size can be acquired. The number of
events would realistically depend on the number of mea-
surements, but by requiring a minimum threshold of
events, and assuming a non-substantial variation in this,
the numbers will nevertheless represent a clinically rele-
vant outcome.
An essential component of the situation matching is the
carbohydrate counting. Patients in Norway are typically
not accustomed to carbohydrate counting, and need to be
educated in how to do this. Hence, all participants will re-
ceive training in carbohydrate counting at the start of the
study. However, whether the training will be adequate for
the study is uncertain, and the results of the study must be
interpreted in this light when applied to regions or coun-
tries where carbohydrate counting is more widespread.
The randomization will not be stratified according to
use of pump or continuous glucose meter (CGM). This
is a potential confounder in the study, but the analysis
can be stratified by pump/CGM use. In addition, the
relatively low sample size of the study means that strati-
fication might lead to under-populated subgroups.
The risk of adverse events in this study is considered
to be negligible, and therefore safety monitoring is not
planned. However, the server data will be accessible tothe team throughout the study, thus if safety concerns
are raised, the data can be investigated.
Diastat requires a significant learning curve, which
may inhibit efficient usage. However, we believe that
there is a need for patient education and understanding
of their condition, and that people with complex and
serious conditions such as T1D are motivated to learn
techniques that can improve their disease management.
The suggested and studied approach focusing on greater
participant involvement in disease management is ambi-
tious, but in line with a recent large increase in patient-
oriented apps and services. We believe this change is ne-
cessary to meet the coming scarcity of healthcare re-
sources, and to make a substantial positive change in the
health outcome of patients with diabetes.
Trial status
At the time of submission, the trial was at the planning
stage and had not yet started recruiting patients.
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